Gabapentin Tablet
Product Images NDC 60760-837

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-837). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clcr (Equation)

Illustration of the Cockcroft-Gault equation formula for estimating creatinine clearance (CLCr), showing calculation based on age, weight, serum creatinine, and a factor adjustment for female patients.*

FDA Label Image

60760-837 (Gabapentin 60760 837 60)

Label for Gabapentin tablets, USP 800 mg, oral tablets, quantity 60. The label includes the National Drug Code (NDC) 60760-837-60, with lot and expiration information not filled. Manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY, and packaged by St. Mary's Medical Park Pharmacy in Oro Valley, AZ. Directions indicate 'USE AS DIRECTED' with storage instructions at 20°-25°C (68°-77°F).*

FDA Label Image

Figure-1 (Figure1)

A line graph showing weekly mean pain scores over 8 weeks in a study comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks including baseline, and the y-axis shows mean pain scores from 0 to 10. Gabapentin group's pain scores decrease over time, while placebo group's scores remain relatively stable.*

FDA Label Image

Figure-2 (Figure2)

Line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2,' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to week 7; the y-axis shows mean pain scores from 0 to 10. Three lines compare Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day during a 3-week dose titration and a 4-week fixed dose period.*

FDA Label Image

Figure-3 (Figure3)

Bar chart showing the proportion of responders (patients with at least 50% reduction in pain score) at endpoint in controlled PHN studies. Study 1 compares placebo (12%) to GBP 3600 (29%). Study 2 compares placebo (14%) to GBP 1800 (32%) and GBP 2400 (34%). Statistical significance is indicated for GBP groups versus placebo.*

FDA Label Image

Figure-4 (Figure4)

A line chart titled 'Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients 12 Years of Age and Older with Partial Seizures.' The x-axis shows daily gabapentin dose in mg (600, 900, 1200, 1800), and the y-axis shows the difference in responder rate percentage, ranging from 2% to 22%. Data points are plotted for three studies labeled a, b, and c, using different square markers. The chart compares differences in responder rates across doses for each study.*

FDA Label Image

Struc (Struct)

Chemical structure diagram of gabapentin, showing a cyclohexane ring bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.